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Carcinoma of the head and neck is a loco-regional disease, which
in many cases may be successfully treated by radiation. The
outcome of curative radiotherapy depends on treatment parameters
such as total dose, dose per fraction and overall treatment time.
Furthermore, a number of tumour- and patient-related factors influ-
ence the outcome of radiotherapy, such as tumour site and size,
stage and histology as well as patient age, sex and general condi-
tion. However, the outcome varies among patients to an extent that
cannot be explained by these factors (Fertil and Malaise, 1981;
Bentzen and Overgaard, 1994), and this observation motivates the
search for new reliable predictors of treatment outcome. Such
predictors could potentially allow individualization of radiotherapy
and thereby, theoretically, improve the outcome both in the
individual patient and at the patient population level.
One potential predictive factor for tumour outcome that has
been studied is the clonogen surviving fraction of cells from
tumour biopsies after a 2 Gy dose, the SF2. In studies on both
human tumour cell lines and primary cultures, SF2 of different
tumour histologies were ranked according to the clinical impres-
sion of radioresponsiveness (Fertil and Malaise, 1981; Deacon et
al, 1984; Fertil and Malaise, 1985; Peters et al, 1988). This gave
rise to studies searching for a correlation between different
measures of tumour radiosensitivity and outcome after radio-
therapy in individual patients. One study of carcinoma of the
uterine cervix reported this kind of correlation using the modified
Courtenay—Mills soft agar clonogenic assay (West et al, 1997).
However, studies of head and neck carcinomas using the cell
adhesion matrix (CAM) assay (Brock et al, 1989; Girinski et al,
1994; Eschwege et al, 1997) failed to demonstrate a correlation
between tumour radiosensitivity and outcome after postoperative
radiotherapy. Similarly, a lack of correlation was shown in
studies using standard clonogenic assays in plastic dishes for
early passage cell lines derived from glioblastoma multiforme,
cervix and head and neck carcinomas (Allalunis-Turner et al,
1992; Schwartz et al, 1992; Taghian et al, 1992). Thus, it is still
unclear whether tumour radiosensitivity, as it is measured with
current assays, may predict the outcome of radiation treatment in
individual patients.
Several studies have examined the relationship between in vitro
radiosensitivity and tumour- and patient-related factors. Studies
on carcinoma of the uterine cervix found measures of tumour
radiosensitivity independent of tumour grade (Allalunis-Turner
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et al, 1991; West et al, 1997), tumour diameter, disease stage and
patient age (West et al, 1997).
The current report is an extension of a study using the modified
Courtenay—Mills soft agar clonogenic assay, to measure in vitro
radiosensitivity in squamous cell carcinomas of the head and neck
(SCCHN) (Stausb¿l-Gr¿n et al, 1995). This previous study drew
attention to the fact that stromal fibroblasts in addition to tumour
cells were colony-forming in soft agar. An immunocytochemical
analysis was developed to identify the origin of the colonies, and
this provided estimates of the radiosensitivity of tumour cells
(tumour cell SF2), stromal fibroblasts (fibroblast SF2), and an
overall estimate (overall SF2) in the same patient. Tumour cell
SF2 did not correlate with either overall SF2 or fibroblast SF2
(Stausb¿l-Gr¿n et al, 1995).
In this paper, further data on the radiosensitivity of SCCHN
are presented, and the relation to clinical and histopathological
data is examined. In addition, the tumour cell and fibroblast
radiosensitivities measured in the same tumour biopsies were
compared.
MATERIALS AND METHODS
Patients and tumour biopsies
Tumour biopsies were obtained from 105 patients with SCCHN at
the Department of Oncology, Aarhus University Hospital and
the Ear, Nose and Throat Departments at Aarhus and Odense
University Hospitals between March 1992 and November 1996.
Informed consent according to the Helsinki Declaration II was
obtained, and the study was approved by the local ethical
committee. Several tumour biopsies were excluded from the
analysis, and the reasons are listed in Figure 1.
In tumour specimens from 71 patients, overall, SF2 tumour cell
and fibroblast SF2 values (measured as joint estimates) were
obtained. Sixty-three patients had primary tumours, and 38
patients were treated with curative radiotherapy alone. Eight
patients had recurrent tumours, six after radiotherapy and two after
surgery. Complete clinical data were available in 63 patients with
primary disease. Among these patients, 18 were female. Median
age was 61 years (range 26—91).
Modified Courtenay–Mills soft agar clonogenic assay
and immunocytochemical staining of colonies
Tumour samples for analysis were achieved under local or general
anaesthesia. The presence of malignancy was checked by routine
histological examination.
The cellular in vitro radiosensitivities were quantified by SF2,
that is the fraction of colony-forming cells after a dose of 2 Gy
relative to that of an unirradiated sample. Tumour cell SF2, fibro-
blast SF2 and an overall SF2 estimate were measured using a modi-
fied Courtenay—Mills soft agar clonogenic assay (Courtenay et al,
1978; Courtenay, 1984; West and Sutherland, 1986) and a colony-
filter technique facilitating immunocytochemical staining, as
previously described (Stausb¿l-Gr¿n et al, 1995).
Tumour biopsies were disaggregated using collagenase, DNase,
and pronase to form a single cell suspension. Following filtration
and assessment of a viable cell count, the cells were plated in soft
agar together with rat red blood cells and an enriched growth
medium consisting of Hams F12, hydrocortisone, insulin, trans-
ferrin, epidermal growth factor and 15% fetal calf serum. The cells
were irradiated 18—20 h after plating using a 250 kV Philips
RT 305 X-ray apparatus yielding a dose rate of 1.59 Gy per min to
the cells. After 4 weeks of incubation in a humidified atmosphere
of 5% O2, 5% CO2, and 90% N2, colonies > 60 mM in diameter
were counted under a stereomicroscope.
After counting the colonies in each culture tube, the agar was
strained off using a 30 mM filter and a Millipore filter system with
vaccum filtration pressure. All the colonies in a culture tube were
collected on a preparation slide. Immunocytochemical identifica-
tion was obtained with different monoclonal antibodies on dupli-
cate slides: broadspectrum anti-cytokeratin antibodies (AE 1—3
Cytokeratin, Biogenex) 1:40, reacting against the cytokeratins in
human epithelia and carcinoma derived from these were used as a
marker for tumour cells (Moll et al, 1982). Fibroblast colonies
were identified using the 5B5 fibroblast antibody (Stausb¿l-Gr¿n
et al, 1995) or anti-vimentin antibody (3B4 1:200, M7020,
DAKO). Anti-vimentin antibody reacts with vimentin, the inter-
mediate filament protein present in cells of mesenchymal origin
as, for example, fibroblasts (Azumi and Battifora, 1987). The
validity of the monoclonal antibodies was tested on cytocentrifuge
preparations and colony slides of an epithelial cell line and
human fibroblast strains as described previously (Stausb¿l-Gr¿n et
al, 1995). Furthermore, tissue sections from SCCHN varying in
tumour differentiation have been tested using both anti-cytokeratin
and anti-vimentin antibodies. The method used for immuno-
staining was an avidin—biotin technique (Stausb¿l-Gr¿n et al,
1995). After immunostaining, the colonies > 60 mM in diameter
were counted and evaluated for staining reaction under a light
microscope. As reported by Courtenay (1984), about 18 cells
could be distinguished on the surface of a 50-cell colony seen from
above or below using a ´ 20 objective to view the individual cells
in a colony.
105 tumour biopsies
from SCC HN
77 tumour biopsies
with assessment of overall SF2
Overall success rate 77/105=73%
74 tumour biopsies giving rise to
detectable tumour cell colonies
71 tumour biopsies giving rise
to joint overall, tumour cell and
fibroblast SF2 estimates:
tumour cell success rate
71/105=68%
Low cell yield/plating efficiency (26)
Contamination (1)
Technical error (1)
Only stomal cell growth (3)
No tumour cell colonies in the 2 Gy tubes (3)
Figure 1 The flow-chart shows the success rates and causes of failures for
cultures of squamous cell carcinoma of the head and neck. The success rate
for measuring tumour cell SF2 was 68%. Low cell yield: fewer than two
culture tubes could be set-up. Low plating efficiency: fewer than ten colonies
in the unirradiated tubes1076 B Stausbøl-Grøn et al
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Table 1 Tumour characteristics and parameters of in vitro radiosensitivity in 63 primary head and neck carcinomas
Site T N M Stage Size Histopathological grade Plating efficiency Overall Tumour cell Fibroblast
classification (mm) of differentiation (%) SF2 SF2 SF2
Oropharynx 2 1 0 3 40 Poor 0.153 0.66 0.19 0.71
Oropharynx 3 3 1 4 60 Poor 0.039 0.65 0.33 0.55
Oropharynx 2 1 0 3 30 Moderate 0.021 0.58 0.25 0.50
Oral cavity 4 2 0 4 40 Poor 0.214 0.35 0.11 0.39
Oral cavity 3 0 0 3 50 Poor 0.046 0.40 0.30 0.40
Oropharynx 2 0 0 2 25 Poor 0.036 0.24 0.67 0.26
Oral cavity 2 0 0 2 20 Moderate 0.181 0.46 0.28 0.47
Oropharynx 1 0 0 1 10 Moderate 0.019 0.44 0.25 0.46
Oropharynx 2 0 0 2 25 Poor 0.074 0.45 0.50 0.53
Oral cavity 2 0 0 2 30 Well 0.313 0.41 0.24 0.48
Oropharynx 2 2 0 4 30 Poor 0.022 0.77 0.50 0.77
Oral cavity 1 0 0 1 15 Moderate 0.040 0.45 0.36 0.46
Hypopharynx 4 0 0 4 40 Moderate 0.168 0.46 0.36 0.44
Oral cavity 2 0 0 2 25 Moderate 0.108 0.70 0.38 0.69
Oropharynx 4 0 0 4 70 Moderate 0.050 0.43 0.41 0.65
Oral cavity 1 0 0 1 18 Well 0.053 0.56 0.75 0.60
Supraglottic 4 0 0 4 35 Poor 0.023 0.42 0.41 0.41
Oropharynx 1 0 0 1 15 Poor 1.447 0.48 0.46 0.49
Oral cavity 3 1 0 3 60 Well 0.005 0.61 0.50 0.75
Oral cavity 2 0 0 2 40 Well 0.013 0.57 0.50 0.58
Hypopharynx 2 0 0 2 40 Moderate 0.021 0.68 0.50 0.44
Oropharynx 2 2 1 4 10 Poor 0.017 0.77 0.67 0.66
Oropharynx 3 1 0 3 45 Poor 0.026 0.67 0.56 0.65
Oral cavity 2 0 0 2 30 Moderate 0.027 0.75 0.43 0.77
Oropharynx 2 0 0 2 30 Moderate 0.037 0.56 0.67 0.57
Oropharynx 3 0 0 3 50 Poor 0.016 0.57 0.48 1.00
Oral cavity 1 0 0 1 15 Well 1.596 0.35 0.53 0.38
Hypopharynx 2 2 0 4 30 Poor 0.291 0.40 0.56 0.49
Oral cavity 1 0 0 1 20 Well 0.200 0.41 0.49 0.37
Oral cavity 2 0 0 2 30 Well 0.014 0.73 0.75 0.78
Oral cavity 1 0 0 1 15 Well 0.219 0.46 0.43 0.49
Oropharynx 2 0 0 2 25 Poor 0.015 0.75 0.59 0.81
Oropharynx 2 2 0 4 30 Moderate 0.027 0.42 0.59 0.43
Oral cavity 1 0 0 1 20 Well 0.214 0.39 0.54 0.32
Oral cavity 2 0 0 2 35 Well 0.149 0.32 0.65 0.45
Oropharynx 1 0 0 1 20 Well 0.031 0.52 0.58 0.62
Oropharynx 3 1 0 3 50 Moderate 0.014 0.60 0.46 0.63
Oral cavity 1 0 0 1 10 Moderate 0.290 0.51 0.66 0.47
Oral cavity 4 2 0 4 75 Poor 0.143 0.49 0.69 0.50
Oral cavity 2 0 0 2 35 Moderate 0.178 0.42 0.64 0.26
Oropharynx 2 0 0 2 40 Well 0.018 0.94 1.00 0.90
Glottic 2 0 0 2 10 Moderate 0.044 0.96 0.93 0.80
Glottic 1 0 0 1 5 Moderate 0.117 0.33 0.75 0.41
Oral cavity 4 3 0 4 30 Poor 0.094 0.60 0.78 0.57
Supraglottic 3 2 0 4 40 Well 0.041 0.76 1.00 0.67
Oral cavity 2 0 0 2 30 Well 0.042 0.51 0.83 0.54
Oral cavity 1 0 0 1 12 Well 0.141 0.67 0.87 0.44
Supraglottic 3 0 0 3 50 Well 0.005 0.79 1.00 0.72
Oropharynx 1 0 0 1 20 Moderate 0.253 0.39 1.00 0.39
Oral cavity 2 1 0 3 30 Moderate 0.033 0.37 0.50 0.34
Maxillary sinus 4 0 0 4 60 Well 0.029 0.46 0.72 0.50
Oral cavity 2 0 0 2 30 Well 0.095 0.30 0.50 0.25
Oral cavity 3 1 0 3 50 Well 0.058 0.49 1.00 0.46
Oropharynx 3 2 0 4 45 Poor 1.026 0.38 0.23 0.39
Oral cavity 1 0 0 1 20 Moderate 0.024 0.48 0.30 0.45
Oral cavity 1 0 0 1 20 Well 0.046 0.38 0.44 0.35
Oropharynx 1 2 0 4 20 Poor 0.650 0.36 0.34 0.36
Oral cavity 1 0 0 1 20 Well 0.118 0.38 0.31 0.38
Oral cavity 2 0 0 2 30 Well 0.125 0.52 0.52 0.52
Oral cavity 2 0 0 2 25 Well 0.038 0.47 0.50 0.49
Oropharynx 1 0 0 1 15 Moderate 0.293 0.51 0.15 0.55
Oropharynx 1 0 0 1 20 Well 0.788 0.27 0.75 0.24
Oral cavity 4 0 0 4 30 Well 0.621 0.38 0.57 0.36Statistical analysis and calculation of the surviving
fraction after 2 Gy
Colony counts were assumed to have a Poisson distribution, and
the standard errors of ratios (like SF2) were calculated using the
normal distribution approximation.
Generally, both the data from the cytokeratin and vimentin
experiments were used to estimate the surviving fractions in order
to reduce the statistical uncertainty of the radiosensitivity estimate
of tumour cells and fibroblasts (Stausb¿l-Gr¿n et al, 1995).
However, the calculation of the surviving fractions was modified
compared to the previous paper (Stausb¿l-Gr¿n et al, 1995), since
the larger sample in the current work made it possible to compare
the two staining procedures statistically. Instead of adding the
colony counts from the two procedures, two separate SF2 values
were estimated, from which a mean value weighted by their
inverse variances was calculated to make a joint estimate. A
motivation for this procedure is given in the Result section below.
The fibroblast colonies were defined as the colonies that were
positively stained with anti-vimentin antibody or were negatively
stained with the anti-cytokeratin antibody. In the same way, the
epithelial tumour colonies were defined as cytokeratin-positive
colonies or vimentin-negative colonies. If no colonies were
obtained in the 2 Gy tubes from the two staining procedures, the
radiosensitivity in question was not achieved. However, if only one
of the SF2 measures was defined, this measure was accepted as the
joint measure of radiosensitivity.
Linear regression was used to test the relationship between
continuous variables of the surviving fraction of tumour cells,
fibroblasts and overall estimates independently measured. Tests
involving tumour cell SF2 were done by weighted linear regres-
sion, weighted with the inverse variance of the tumour cell SF2.
Thereby, the low number of tumour cell colonies was taken into
account by weighting the best-determined tumour cell SF2 values
the most. When correlating the radiosensitivities independently
measured in the individual patients, the tumour cell SF2 was
calculated from the positive colonies in the cytokeratin-stained
slides or from the negative colonies in the vimentin-stained
slides. Similarly, the fibroblast SF2 was calculated from the
positive colonies in the vimentin-stained slides or from the
negative colonies in the cytokeratin-stained slides. The overall SF2
estimates were calculated from the total number of colonies in the
cytokeratin- or in the vimentin-stained slides.
Spearman correlation test was used to examine the relationship
between the in vitro radiosensitivities and ordinal clinical and
histopathological parameters, e.g. stage or grade. In all cases, a
significance level of 5% was used. All P-values given in the text
are from two-sided tests.
Clinical and histopathological parameters
In the analyses, the site of the primary tumours was classified
according to the International Union against Cancer￿s (UICC)
TNM (Tumour, Node, Metastasis) classification of malignant
tumours (1987). Similarly for staging, which was obtained by
clinical examination, X-ray examination and computed tomog-
raphy. Tumour size was recorded as the largest dimension
measured clinically.
For routine histopathological examination, specimens were
obtained mostly in parallel with the specimen for radiosensitivity
testing. Histological sections (3 mM) were cut from formalin-fixed
and paraffin-embedded specimens, and histopathological differen-
tiation was graded as well, moderately and poorly differentiated,
according to Broders (1920).
The clinical and histopathological characteristics in addition to
the radiosensitivity data in 63 patients with primary tumours are
listed in Table 1.
RESULTS
Validation of the assay for radiosensitivity testing
In addition to the modified Courtenay—Mills soft agar clonogenic
assay, an immunocytochemical analysis was used and evaluated in
the current study.
Biopsy material was obtained from 105 patients with SCCHN.
In 26 cases, the cell yield was too low for plating two culture tubes,
or plating efficiency was low with fewer than ten colonies in the
unirradiated tubes. Data on the overall in vitro radiosensitivity was
obtained in 77 patient biopsies, which all met the criteria for
successful growth with more than ten colonies in the unirradiated
tubes. The overall success rate was 73%. However, only stromal
fibroblast growth was obtained in three of the tumour biopsies.
Hence, it was possible to detect tumour cell growth in 74 tumour
biopsies. But, in three of the tumour biopsies, no tumour cell
colonies were obtained in the 2-Gy tubes and these were excluded
from analyses of SF2 values (Figure 1). The plating efficiency for
all cells (e.g. tumour cells and fibroblasts) ranged from 0.005 to
1.60% with a median of 0.052%.
The reliability of the immunocytochemical analysis using cyto-
keratin and vimentin antibodies to detect epithelial cells and fibro-
blasts, respectively, was tested on sections of SCCHN (Figure 2).
Using the colony-filter technique and immunocytochemistry, it was
possible to estimate the numbers of both tumour cell colonies and
fibroblast colonies. Typical tumour cell colonies and fibroblast
colonies are shown in Figure 2. The majority of the colonies
obtained from the tumour biopsies were fibroblast marker-positive,
and the tumour marker-positive colonies ranged from 1 to 88%
with a median of only 15% in the control tubes (Figure 3).
Due to the larger number of patients compared to the previous
paper (Stausb¿l-Gr¿n et al, 1995), the methodological quality of the
immunocytochemical staining using two monoclonal antibodies
could be evaluated statistically. Before estimating a joint SF2 value
from the results of the two staining procedures, the monoclonal
antibodies ought to provide the same measure of colony-forming
capacity both in the control and the irradiated tubes. As shown in
Figure 4, colony counts from the two staining procedures were
significantly correlated and proportional, but for the fibroblast
colonies, the slope of the regression line was significantly different
from 1. This may suggest an observer bias where negative colonies
were overlooked to some extent. However, the SF2 value is the ratio
between colony counts at 2 Gy and 0 Gy. Therefore, the constant of
proportionality cancels out, and the SF2 values estimated from the
two staining procedures should be comparable. Thus, both
measures of radiosensitivity were entered in the calculations, and a
mean value weighted by the separate inverse variances was calcu-
lated to take into account the uncertainty in the separate SF2
measures.
The joint estimates of radiosensitivity varied considerably. The
overall SF2 ranged from 0.24 to 0.96 with the median overall SF2
being 0.47, the median tumour cell SF2 was 0.50 (range 0.11—1.0)
and the median fibroblast SF2 was 0.49 (range 0.24—1.0).
In vitro radiosensitivity of tumour cells and fibroblasts 1077
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Figure 2 Immunostaining of serial sections (´ 50) and colonies (´ 400) obtained from pretreatment head and neck squamous cell carcinoma specimens. Left
panel: expression of cytokeratin using cytokeratin antibodies AE1-3 (1:40). Right panel: vimentin expression using vimentin antibody 3B4 (1:200). The colonies
are typical tumour cell colonies (T) and fibroblast colonies (F), respectively, according to the definitions in the textIn vitro radiosensitivity of tumour cells and fibroblasts 1079
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It was not possible to examine for intra-tumour heterogeneity,
since the tumour material obtained was limited. However, the
relationship between independent measures of SF2 obtained
within the same tumour biopsy was examined using a linear
regression analysis (Table 2). Sufficient colony tubes/slides for
staining with both anti-cytokeratin and anti-vimentin were
obtained in 71 patients. The assay reproducibility was tested by
comparing one measure of overall SF2 (total number of colonies
in anti-cytokeratin-stained slides) with another measure of overall
SF2 (total number of colonies in anti-vimentin-stained slides),
and these measures were significantly correlated. The fibroblast
SF2 (fibroblast marker-positive colonies) and a fibroblast SF2
measured independently of the latter (tumour marker-negative
colonies) correlated significantly in 69 patients. Furthermore, in
43 patients with two independent measures of tumour cell SF2, the
variation in tumour cell SF2 was examined using weighted linear
regression, to be able to give the best determined SF2 value the
highest weight. Tumour cell SF2 (tumour marker-positive
colonies) was significantly correlated to another measure of
tumour cell SF2 (fibroblast marker-negative colonies).
In conclusion, the present assay for radiosensitivity testing was
validated, and it was reproducible for overall SF2, fibroblast SF2
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and tumour cell SF2. Among patients, it was possible to measure a
large variation in inter-tumour in vitro radiosensitivity of tumour
cells and fibroblasts, and the overall estimate. Finally, the main
problems displayed were the low plating efficiencies and the low
number of tumour cell colonies, when growing cells from tumour
specimens in the modified Courtenay—Mills soft agar clonogenic
assay.
Relationship between the radiosensitivity of tumour
cells and fibroblasts
This study was an attempt to investigate the radiation biology in
tumours, and to compare the in vitro radiosensitivity of fibroblasts
and tumour cells.
In order to ensure statistical independence of the variables, a
linear regression analysis was performed to test the relationship
between various measures of SF2. Table 3 shows a comparison of
the separately measured radiosensitivities of tumour cells and
fibroblasts, and an overall estimate. In 71 patients, overall SF2
(total number of colonies in anti-cytokeratin-stained slides) corre-
lated significantly with the fibroblast SF2 (fibroblast marker-posi-
tive colonies) (Figure 5A). This meant that the standard measure of
tumour radiosensitivity in many studies, the overall SF2, was
correlated with the sensitivity of the stromal fibroblasts. In
contrast, the overall SF2 (total number of colonies in anti-
vimentin-stained slides) did not correlate with the tumour cell SF2
(tumour marker-positive colonies) in 63 patients using weighted
linear regression, taking into account the statistical precision of
tumour cell SF2 (Figure 5B).
Tumour cell SF2 (tumour marker-positive colonies), and fibro-
blast SF2 (fibroblast marker-positive colonies) measured in the same
individual were not correlated. The correlation coefficient was 0.06
with 95% confidence interval (CI) (—0.19; 0.30) (Figure 5C). A
previous published paper on 12 of the patients also demonstrated a
lack of correlation between the radiosensitivity of tumour cells and
fibroblasts (Stausb¿l-Gr¿n et al, 1995) and this was confirmed in an
analysis leaving out the first 12 patients (r = 0.06, 95% CI [—0.21;
0.33]). Thus, the data preclude any strong correlation between
tumour and fibroblast radiosensitivity as assessed here.
Relationship between cellular in vitro radiosensitivities
and clinical data
Table 1 shows the tumour characteristics and the parameters of
radiosensitivity in SCCHN from 63 patients with primary disease.
Large tumours were found to have lower overall plating efficien-
cies than small tumours (n = 63, r = —0.32, 2P = 0.011). The same
correlation was found for T-category when related to plating
efficiency (n = 63, r = —0.28, 2P = 0.027). Furthermore, plating
efficiencies were higher in tumours from younger patients than
older patients (n = 63, r = —0.32, 2P = 0.011). No correlation was
found between overall plating efficiency and overall SF2, tumour
cell SF2 or fibroblast SF2.
Overall SF2 and tumour cell SF2 were not correlated with
T- and N-category, stage, tumour size, sex and age. However,
the tumour cell SF2 values were lower in the poorly differenti-
ated tumours than in the well- and moderately differentiated
tumours, which suggests that the well-differentiated tumours
were more radioresistant (Figure 6). This relationship was not
statistically significant for the overall SF2 (2P = 0.65), or the
fibroblast SF2 (2P = 0.38). Obviously, this finding should be
seen in light of the rather high number of statistical tests
performed. However, tumour cell radiosensitivity increased
with decreasing tumour differentiation (r = —0.34, 2P = 0.056)
in our previous study on 31 patients with SCCHN (Stausb¿l-
Gr¿n et al, 1996). Excluding the 31 patients from the analysis
of the 63 patients with primary tumours in the current study,
the same trend was found in the remaining patients (r = —0.34,
Table 2 Correlation between independent experiments in the same tumour biopsy examining reproducibility
Variables nr 2P-value Analysis
Overall SF2 (ck) Overall SF2 (vim) 71 0.55 < 0.001 Linear regression
Fibroblast SF2 (vim+) Fibroblast SF2 (ck–) 69a 0.43 0.001 Linear regression
Tumour cell SF2 (ck+) Tumour cell SF2 (vim–) 43b 0.31 0.046 Weighted regressionc
aFibroblast SF2 (ck–) with non-zero colony count at 2 Gy. bTumour cell SF2 (ck+) and tumour cell SF2 (vim–)
with non-zero colony count at 2 Gy. cWeighted with the statistical precision on tumour cell SF2 (ck+) and
tumour cell SF2 (vim–). ck = tumour marker; vim = fibroblast marker; +/– = positive/negative reaction
Table 3 Correlation between measures of radiosensitivity with respect to cell type in the same individual
Variables nr 2P-value Analysis
Overall SF2 (ck) Fibroblast SF2 (vim+) 71 0.33 0.006 Linear regression
Overall SF2 (vim) Tumour cell SF2 (ck+) 63a 0.11 0.388 Weighted regressionb
Fibroblast SF2 (vim+) Tumour cell SF2 (ck+) 63a 0.06 0.643 Weighted regressionb
aTumour cell SF2 (ck+) with non-zero colony count at 2 Gy. bWeighted with the statistical precision on tumour
cell SF2 (ck+). ck = tumour marker; vim = fibroblast marker; + = positive reaction.In vitro radiosensitivity of tumour cells and fibroblasts 1081
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2P = 0.052). Thus, the consistency of two independent analyses
adds credibility to the finding.
DISCUSSION
In vitro radiosensitivity of tumour cells and fibroblasts within an
individual were not correlated in squamous cell carcinomas of the
head and neck under the assay conditions described above. In
addition, the poorly differentiated tumours were more radiosensi-
tive, measured by tumour cell SF2, than the well- and moderately
differentiated tumours. To judge the representativeness of these
findings, it is of interest to compare our assay with reports in the
literature.
The assay used in the current study was similar to the often used
modified Courtenay—Mills soft agar clonogenic assay (West et al,
1989, 1993), except for the addition of an immunocytochemical
analysis for staining colonies from soft agar (Stausb¿l-Gr¿n et al,
1995). The 73% overall success rate in this study is consistent with
the overall success rate in previous studies on cellular in vitro
radiosensitivity of different tumour types using either CAM assays
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Figure 5 The relationship between different measures of in vitro radiosensitivity in the same individual with respect to cell-type. (A) A correlation between
overall SF2 and fibroblast SF2 was found (n = 71, r = 0.33, 2P = 0.006; (0.33, 2.00), not shown). (B) Overall SF2 and tumour cell SF2 did not correlate (n = 63,
r = 0.11, 2P = 0.39). (C) No correlation was found between the tumour cell radiosensitivity and the fibroblast radiosensitivity (n = 63, r = 0.06, 2P = 0.64; (2.00,
0.43), not shown)1082 B Stausbøl-Grøn et al
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or soft agar clonogenic assays (Brock et al, 1990; Girinski and
Fertil, 1993; Kocag￿nc￿ et al, 1994; West, 1995). The success rate
for measuring tumour cell radiosensitivity was 68%. Furthermore,
the plating efficiency and the overall SF2 values measured in this
study fell within the same range as in similar studies on in vitro
radiosensitivity (Brock et al, 1989; West et al, 1989, 1993; Girinski
et al, 1994; Kocag￿nc￿ et al, 1994; West, 1995).
Measuring cell-type specific radiosensitivity required the use
of monoclonal antibodies. Cytokeratins are characteristic of
epithelial cells (Moll et al, 1982), and anti-cytokeratin antibodies
with broad specificity were used as tumour cell markers, whereas
5B5 fibroblast antibody and anti-vimentin antibody were used as
fibroblast markers. Presumably, it may be an advantage to use a
panel of antibodies to different relevant markers, e.g. different
intermediate filaments (Suo et al, 1992) for identifying cell types
with a reasonable degree of certainty. Haustermans et al (1996)
have identified cytokeratin antibodies that will stain a high
proportion of head and neck cancers with no, or very little,
staining of stromal cells. However, the ability of tumours to show
coexpression of cytokeratin and vimentin has been demonstrated
in some carcinomas (Azumi and Battifora, 1987). This may
constitute a pitfall and influence the interpretation of the results.
In this study, immunostaining of sections from SCCHN showed
reliable staining. The anti-cytokeratin antibodies stained
epithelia and tumour cells, and anti-vimentin antibody stained
stromal cells. Such a reasonable agreement between the reactions
of these antibodies is a prerequisite for using the data from both
markers.
In contrast to Davidson et al (1990), it was not possible to
examine tumour heterogeneity due to limited tumour material.
Yet, within each single tumour biopsy separately measured
overall SF2 (fibroblast marker/tumour marker), fibroblast SF2
(fibroblast marker-positive/tumour marker-negative colonies)
and tumour cell SF2 (tumour marker-positive/fibroblast marker-
negative colonies) estimates correlated significantly. But the
low correlation coefficients suggest a high level of noise
in the modified Courtenay—Mills soft agar clonogenic assay.
Furthermore, the immunocytochemical analysis indicated that
only a small fraction of the colonies was tumour marker-positive
when culturing cells from SCCHN. Approximately 70% of the
tumours yielded less than 20% tumour cell colonies in both the
control and the irradiated tubes. This low number of tumour cell
colonies causes a considerable uncertainty in the measure of
tumour cell radiosensitivity estimating tumour cells SF2 values
of 1 and more, due to random fluctuations in the colony counts
at 0 and 2 Gy. One may exclude the tumour biopsies that reach
less than a certain number of tumour cell colonies from the
analysis, but the cut-off point will be arbitrary. An alternative
may be to take all the available data into account and calculate
a mean SF2 value weighted by the inverse variances, and to
do weighted linear regression tests weighted with the statistical
precision on SF2. In this study, the weighted linear regression
test was preferred in the case of the tumour cell SF2, because
of the low number of tumour cell colonies. This meant that the
best determined SF2 values were given more weight. However,
a minimum requirement of three tumour cell colonies in the
culture tubes was implemented. This resulted in the exclusion
of many patients, but the main conclusions were unchanged.
Finally, it may be concluded that the low number of tumour
cell colonies and low plating efficiencies are the main
methodological problems when culturing primary specimens
from SCCHN in the modified Courtenay—Mills soft agar clono-
genic assay.
The current method has been shown to be suitable for studies of
fibroblast and tumour cell radiosensitivity in the same tumour and
individual, which in turn may provide valuable biological insights
into the possible correlation between the sensitivity of normal and
tumour cells (Stausb¿l-Gr¿n et al, 1998). Individual in vitro
radiosensitivities of tumour cells and fibroblasts as assessed here
were not correlated in SCCHN. In agreement with this finding, in
vitro studies reviewed by Bentzen and Overgaard (1994) found a
lack of correlation between the in vitro radiosensitivity of various
normal cell types in the same person. However, one study has
reported a link between the in vitro radiosensitivity of fibroblasts
and sarcoma cells in the same patient (Dahlberg et al, 1993).
A range of clinical studies (Tucker et al, 1992; Bentzen and
Overgaard, 1994; Geara et al, 1996; Bentzen, 1997; Bernier et al,
1998) have suggested that the individual differences in radiosensi-
tivity are not dominated by a common genetically determined factor
expressed equally in all cells. This provides indirect support for a
real biological difference in tumour cell and fibroblast radiosensi-
tivity in SCCHN. Two studies did find a correlation between indi-
vidual patient sensitivity of early mucosal reactions and radiation
response of tumours derived from the same tissue (Bujko et al, 1994;
Dahl et al, 1994), but these findings may need to be validated by
other studies (Bentzen, 1997). Thus, a correction for the contamina-
tion of fibroblasts and a separate measurement of tumour cell
radiosensitivity may be necessary, when studying tumour radiosen-
sitivity and tumour response to radiation, but to what extent tumour
cell SF2 is predictive for treatment outcome is still not clear.
If the cellular in vitro radiosensitivity is to be a clinically useful
predictive parameter, it must supplement the information from
known prognostic factors. Yet, a lack of correlation between in
vitro radiosensitivity and clinical data may be influenced by
fibroblast contamination in the cultures. In this study, no signifi-
cant correlations were found between overall SF2 and clinical and
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Figure 6 The correlation between tumour cell radiosensitivity and the
histopathological grade of differentiation in 63 primary tumours (r = –0.32,
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histopathological parameters. Furthermore, tumour cell radio-
sensitivity and T- and N-category, stage, tumour size, sex and age
were not significantly associated.
However, in vitro radiosensitivity of tumour cells and tumour
differentiation were statistically significantly correlated with the
well- and moderately differentiated tumours being more radiore-
sistant than the poorly differentiated tumours. But the correlation
was not conspicuous, as seen from Figure 4. One may argue
whether this relationship is a biological finding, suggesting that
the tumour cell SF2 is a more reliable measure of tumour
radiosensitivity than the overall SF2, or simply a result of
multiple comparisons. In analysis of many parameters, the prob-
ability of finding a significant difference just by chance increases
with the number of tests performed (Beck-Bornholdt and
Dubben, 1994). However, in this study a subset consisting of 31
patients was previously analysed in what might be regarded as a
hypothesis-generating analysis (Stausb¿l-Gr¿n et al, 1996). A
relationship between tumour cell SF2 and differentiation was
seen with a tendency for well-differentiated tumours to be more
resistant. This trend was also seen in an independent group of the
remaining patients, which supports that this is not just a spurious
finding.
Recently, it was suggested that well-differentiated carcinomas
of the head and neck respond to a radiation trauma with acceler-
ated repopulation just like the normal mucosa, and that these
tumours may benefit from reduced overall treatment time (Hansen
et al, 1997). In the present study, the poorly differentiated tumours
appeared to be the most radiosensitive, measured by tumour cell
SF2. Taken together, these observations, if substantiated, could
argue in favour of a reduced overall treatment time, even at the
expense of a decreased total dose such as the randomized trial of
continuous, hyperfractionated, accelerated radiotherapy (CHART)
(Dische et al, 1997).
Finally, it remains to be tested whether estimates of radiosensi-
tivity are useful predictors of the response to radiotherapy.
Unfortunately, it may not be possible to test if measured fibroblast
radiosensitivity predicts normal tissue response in patients, since
the clinical data have not been collected. The low number of
tumour cell colonies obtained from primary tumours in the modi-
fied Courtenay—Mills soft agar clonogenic assay may result in a
too uncertain measure of tumour cell radiosensitivity to allow
prediction of the tumour response to radiotherapy. However, it is
well-established that the tumour response is dependent on other
factors, for instance tumour oxygenation status (Nordsmark et al,
1996) and patient-related factors (Bentzen and Overgaard, 1994),
probably making it difficult to predict clinical outcome from
cellular in vitro radiosensitivity alone.
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